Pharmacom Net Tangible Assets from 2010 to 2024
| PHMB Stock | USD 0.0001 0.00 0.00% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 53.3 K | Current Value 55.9 K | Quarterly Volatility 12.9 K |
Check Pharmacom Biovet financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharmacom Biovet's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 475.5 K or Total Revenue of 0.0, as well as many indicators such as . Pharmacom financial statements analysis is a perfect complement when working with Pharmacom Biovet Valuation or Volatility modules.
Pharmacom | Net Tangible Assets |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pharmacom Biovet offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Pharmacom Biovet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacom Biovet Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacom Biovet Stock:Check out the analysis of Pharmacom Biovet Correlation against competitors. For information on how to trade Pharmacom Stock refer to our How to Trade Pharmacom Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharmacom Biovet. If investors know Pharmacom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pharmacom Biovet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pharmacom Biovet is measured differently than its book value, which is the value of Pharmacom that is recorded on the company's balance sheet. Investors also form their own opinion of Pharmacom Biovet's value that differs from its market value or its book value, called intrinsic value, which is Pharmacom Biovet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pharmacom Biovet's market value can be influenced by many factors that don't directly affect Pharmacom Biovet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pharmacom Biovet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pharmacom Biovet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pharmacom Biovet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.